




RealRate

PHARMACEUTICAL 2010

ELI Lilly Co
Rank 8 of 8

Lilly



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 25% points. The greatest weakness of ELI Lilly Co is the variable Stockholders Equity, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 98% points below the market average of 337%.

Input Variable	Value in 1000 USD
Assets, Current	12,486,500
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,568,100
Liabilities, Non-Current	11,367,500
Other Assets	6,777,000
Other Compr. Net Income	314,900
Other Expenses	6,288,200
Other Liabilities	0
Other Net Income	0
Other Revenues	21,836,000
Property and Equipment	8,197,400
Research and Development	4,326,500
Selling, General and Administrative Expense	6,892,500

Output Variable	Value in 1000 USD
Assets	27,460,900
Liabilities	17,935,600
Expenses	17,507,200
Revenues	21,836,000
Stockholders Equity	9,525,300
Net Income	4,328,800
Comprehensive Net Income	4,486,250
BaseVar	42,527,300
ECR before LimitedLiability	111%
Economic Capital Ratio	239%